Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Tara Elisabeth Seery,Chaitali Singh Nangia,Leonard S. Sender,Sandeep K. Reddy,Patrick Soon-Shiong

Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

2021

Tara Elisabeth Seery
Chaitali Singh Nangia
Leonard S. Sender
Sandeep K. Reddy
Patrick Soon-Shiong

TPS4174Background: Pancreatic cancer will claim an estimated 47,050 lives in the USA in 2020, with an expected 5 year survival of 10%. Thus there is an urgent need for novel treatment options in th...

Keywords:

treatment options
Medicine
Internal medicine
locally advanced
Pancreatic cancer
Oncology
Chemotherapy
standard of care
combination immunotherapy
Metastatic pancreatic cancer
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations